{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:26:16Z","timestamp":1772843176828,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jdermsci.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:16:02Z","timestamp":1621556162000},"page":"2-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Advances in gene therapy and their application to skin diseases: A review"],"prefix":"10.1016","volume":"103","author":[{"given":"Satoru","family":"Shinkuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5058","key":"10.1016\/j.jdermsci.2021.05.004_bib0005","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.256.5058.808","article-title":"Human gene therapy","volume":"256","author":"Anderson","year":"1992","journal-title":"Science"},{"issue":"5466","key":"10.1016\/j.jdermsci.2021.05.004_bib0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jdermsci.2021.05.004_bib0015","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood-2002-07-2314","article-title":"Side effects of retroviral gene transfer into hematopoietic stem cells","volume":"101","author":"Baum","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.05.004_bib0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency","volume":"13","author":"Raper","year":"2002","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.jdermsci.2021.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4889(03)00024-7","article-title":"Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy","volume":"1640","author":"Brenner","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.jdermsci.2021.05.004_bib0030","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s11262-017-1489-0","article-title":"The retroviral vector family: something for everyone","volume":"53","author":"Elsner","year":"2017","journal-title":"Virus Genes"},{"issue":"4","key":"10.1016\/j.jdermsci.2021.05.004_bib0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/mp.53.4.173","article-title":"Retroviral vectors","volume":"53","author":"Kurian","year":"2000","journal-title":"Mol. Pathol."},{"issue":"4","key":"10.1016\/j.jdermsci.2021.05.004_bib0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clindermatol.2011.01.010","article-title":"Ultrastructure and molecular pathogenesis of epidermolysis bullosa","volume":"29","author":"Shinkuma","year":"2011","journal-title":"Clin. Dermatol."},{"issue":"12","key":"10.1016\/j.jdermsci.2021.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jdermsci.2021.05.004_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.stemcr.2013.11.001","article-title":"Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa","volume":"2","author":"De Rosa","year":"2014","journal-title":"Stem Cell Rep."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.05.004_bib0055","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jid.2016.10.038","article-title":"Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells","volume":"137","author":"Bauer","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"7680","key":"10.1016\/j.jdermsci.2021.05.004_bib0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.jdermsci.2021.05.004_bib0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"issue":"17","key":"10.1016\/j.jdermsci.2021.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jdermsci.2021.05.004_bib0075","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/bies.201500051","article-title":"Retroviral integration: site matters: mechanisms and consequences of retroviral integration site selection","volume":"37","author":"Demeulemeester","year":"2015","journal-title":"BioEssays"},{"issue":"18","key":"10.1016\/j.jdermsci.2021.05.004_bib0080","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6212","key":"10.1016\/j.jdermsci.2021.05.004_bib0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/338254a0","article-title":"The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA","volume":"338","author":"Malim","year":"1989","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jdermsci.2021.05.004_bib0090","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11684-011-0159-1","article-title":"Stem cell gene therapy: The risks of insertional mutagenesis and approaches to minimize genotoxicity","volume":"5","author":"Wu","year":"2011","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.jdermsci.2021.05.004_bib0095","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jid.2016.02.811","article-title":"Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a self-inactivating COL7A1 retroviral vector","volume":"136","author":"Jack\u00f3w","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.jdermsci.2021.05.004_bib0100","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1089\/hum.2019.049","article-title":"Generation and clinical application of gene-modified autologous epidermal sheets in netherton syndrome: lessons learned from a Phase 1 trial","volume":"30","author":"Di","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.jdermsci.2021.05.004_bib0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jdermsci.2019.06.007","article-title":"Physiological and pathological roles of kallikrein-related peptidases in the epidermis","volume":"95","author":"Kishibe","year":"2019","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.05.004_bib0110","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/bjd.18559","article-title":"EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I\/II gene therapy trial for recessive dystrophic epidermolysis bullosa","volume":"182","author":"Gaucher","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.05.004_bib0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40291-020-00466-7","article-title":"Molecular Therapeutics in development for epidermolysis bullosa: Update","volume":"2020","author":"Has","year":"2020","journal-title":"Mol. Diagn. Ther."},{"issue":"11","key":"10.1016\/j.jdermsci.2021.05.004_bib0120","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.jdermsci.2021.05.004_bib0125","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"22","key":"10.1016\/j.jdermsci.2021.05.004_bib0130","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jdermsci.2021.05.004_bib0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jdermsci.2021.05.004_bib0140","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/mt.2008.32","article-title":"Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma","volume":"16","author":"Dummer","year":"2008","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.05.004_bib0145","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.gt.3300833","article-title":"Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial","volume":"6","author":"Stewart","year":"1999","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.jdermsci.2021.05.004_bib0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.cgt.7700214","article-title":"Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumours","volume":"7","author":"Dummer","year":"2000","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"10.1016\/j.jdermsci.2021.05.004_bib0155","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumour regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jdermsci.2021.05.004_bib0160","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/mt.2010.52","article-title":"Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas","volume":"18","author":"Dummer","year":"2010","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.jdermsci.2021.05.004_bib0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.jdermsci.2021.05.004_bib0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors","volume":"5","author":"Gao","year":"2005","journal-title":"Curr. Gene Ther."},{"issue":"2","key":"10.1016\/j.jdermsci.2021.05.004_bib0175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/biom11020271","article-title":"Fabry disease: Molecular basis, pathophysiology, diagnostics and potential therapeutic directions","volume":"11","author":"Kok","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.jdermsci.2021.05.004_bib0180","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/diseases6030074","article-title":"Herpes simplex virus vectors for gene transfer to the central nervous system","volume":"6","author":"Artusi","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.jdermsci.2021.05.004_bib0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.jdermsci.2021.05.004_bib0190","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/imt-2019-0033","article-title":"Talimogene laherparepvec: Review of its mechanism of action and clinical efficacy and safety","volume":"11","author":"Raman","year":"2019","journal-title":"Immunotherapy"},{"issue":"29","key":"10.1016\/j.jdermsci.2021.05.004_bib0195","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jdermsci.2021.05.004_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.08.018","article-title":"QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study","volume":"141","author":"Bornert","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"7042","key":"10.1016\/j.jdermsci.2021.05.004_bib0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature03556","article-title":"Highly efficient endogenous human gene correction using designed zinc-finger nucleases","volume":"435","author":"Urnov","year":"2005","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jdermsci.2021.05.004_bib0210","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"issue":"12","key":"10.1016\/j.jdermsci.2021.05.004_bib0215","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/nar\/gkr218","article-title":"Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting","volume":"39","author":"Cermak","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"6096","key":"10.1016\/j.jdermsci.2021.05.004_bib0220","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.05.004_bib0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/cells9010112","article-title":"Context-dependent strategies for enhanced genome editing of genodermatoses","volume":"9","author":"March","year":"2020","journal-title":"Cells"},{"issue":"20","key":"10.1016\/j.jdermsci.2021.05.004_bib0230","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1073\/pnas.1512028113","article-title":"Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa","volume":"113","author":"Shinkuma","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.jdermsci.2021.05.004_bib0235","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jid.2019.02.015","article-title":"Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR\/Cas9","volume":"139","author":"Takashima","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.05.004_bib0240","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR correction of Duchenne muscular dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.05.004_bib0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jdermsci.2020.04.004","article-title":"Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR\/Cas9 and piggyBac transposon system","volume":"98","author":"Itoh","year":"2020","journal-title":"J. Dermatol. Sci."},{"issue":"52","key":"10.1016\/j.jdermsci.2021.05.004_bib0250","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Jack\u00f3w","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:51:44Z","timestamp":1760331104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181121001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0923181121001109"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.05.004","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in gene therapy and their application to skin diseases: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}